believe trial semaglutide BELIEVE - GLP-1 muscle loss study Trial The BELIEVE Trial: Revolutionizing Weight Loss with Semaglutide and Bimagrumab

New GLP-1 retatrutide The pursuit of effective weight management solutions has taken a significant leap forward with the BELIEVE trial, investigating the combined efficacy of semaglutide and bimagrumab作者：V Aimelet·2025—...semaglutideand bimagrumab led to a 70% reduction in fat mass without any loss of fat‐free mass. Furthermore, results from theBELIEVEPhase 2btrialshow .... This groundbreaking research focuses on a critical aspect often overlooked in weight loss: preserving muscle mass while effectively reducing fat.Bimagrumab: Novel Medical Therapy for Inclusion Body... Emerging data from the BELIEVE trial suggest a promising future for individuals struggling with overweight and obesity, offering a pathway to not only shed pounds but to do so in a healthier, more sustainable manner.

Recent findings presented at various medical conferences in 2025 highlight the success of this combination therapy. The BELIEVE Phase 2b trial, a randomized, double-blind, placebo-controlled study, enrolled approximately 500 participants across 26 centers in the United States, Australia, and New Zealand. These participants were evaluated over a 72-week period to assess the impact of semaglutide (administered subcutaneously) combined with intravenous bimagrumab. The study's design specifically aimed to understand how this combination therapy could influence body composition.

One of the most compelling outcomes from the BELIEVE study is the significant reduction in fat mass observed in participants receiving the bimagrumab and semaglutide combination. Reports indicate an approximate 70% reduction in fat mass without a commensurate loss of fat-free mass. This contrasts with some other weight loss approaches, where a substantial percentage of weight loss can be attributed to lean muscle tissue2023年6月21日—...semaglutidein patients with obesity aims to evaluate its potential to ... "Achieving our enrollment target in theBELIEVEstudy is an .... For instance, some studies on semaglutide monotherapy over 52 weeks have shown a roughly 60% fat mass loss alongside a 40% lean soft tissue loss, underscoring the potential advantage of the combined approach.New GLP-1 pill orforglipron outperforms oral semaglutide ...

Bimagrumab, an activin type II receptor-targeted antibody, plays a crucial role in promoting muscle growth. By combining its muscle-preserving capabilities with the potent appetite-suppressing and glucose-regulating effects of semaglutide, researchers are achieving a nuanced approach to weight loss. Experts believe this synergy is key to achieving a higher quality of weight loss, where the loss is primarily composed of adipose tissue while essential muscle mass is maintained or even increased.作者：M Kaiser—TheBELIEVEPhase 2btrialevaluated the combination of bimagrumab andsemaglutidefor preserving muscle in obese adults.12Bimagrumab is ... Earlier data from precursor studies have hinted at a 20.5% decline in fat mass and a 3.6% increase in lean mass with similar interventions.

The BELIEVE trial's methodology is robust, characteristic of a well-designed trial. Participants received either a placebo or bimagrumab, with some also receiving semaglutide. The results have been widely discussed, with many researchers anticipating positive outcomes for future obesity treatment strategies. The BELIEVE study specifically targets individuals who are overweight or obese but do not have diabetes, allowing for a focused evaluation of its effects on body composition.

The implications of the BELIEVE trial extend beyond mere weight reduction. The preservation of lean muscle mass is vital for maintaining metabolic rate, physical function, and overall healthA multinational, double-blind, placebo-controlled, Phase 2 study of bimagrumab and/orsemaglutidein people with obesity/overweight without diabetes.. Losing significant muscle can lead to a decrease in basal metabolic rate, making it harder to maintain weight loss in the long term and potentially contributing to sarcopenia, the age-related loss of muscle mass作者：J Deanfield·2025·被引用次数：26—Department of Endocrinology, Obesity and Nutrition, Vestfold Hospital Trust, Norway ... The SELECTtrialfoundsemaglutidereduced major adverse .... The bimagrumab + semaglutide combination appears to mitigate this risk, offering a more holistic approach to healthSemaglutide2.4 mg over 52 weeks yields about 60% fat mass loss and 40% lean soft tissue loss; Tirzepatide over 72 weeks shows 74% fat mass loss and 25% lean ....

While semaglutide has already demonstrated significant efficacy in weight loss and cardiovascular outcome improvements (as seen in the SELECT trial), the integration of bimagrumab addresses a critical unmet need in optimizing the composition of that weight loss.作者：G Halsey—In the Phase 2bBELIEVE trial, participants receiving a combination ... The 507 participants inBELIEVEreceivedsemaglutideas a once ... The data emerging from this trial are generating considerable excitement within the medical community, with many anticipating the potential for these findings to reshape obesity treatment paradigms. The BELIEVE trial is a testament to the ongoing innovation in pharmaceutical research, pushing the boundaries of what is possible in managing complex health conditions like obesity.TheBELIEVE trialhas shown that a combination of intravenous bimagrumab and subcutaneoussemaglutideleads to significant weight loss and fat mass ... The trial's completion of enrollment at Versanis Bio in June 2023 marked a significant milestone, paving the way for these impactful results to be shared more broadly.NCT05616013 | Safety and Efficacy of Bimagrumab and ...